PBF-680(PBF-680) - 药物靶点：A1R_在研适应症：慢性阻塞性肺疾病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

A1R

作用机制

A1R拮抗剂(腺苷A1受体拮抗剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

7

项与 PBF-680 相关的临床试验

NCT05262218

/ Completed临床2期

A Phase IIa, Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of PBF-680 in Patients With Moderate to Severe COPD on Top of the Standard Medication

The purpose of the study is to investigate the effect of PBF-680 on the chronic inflammation and the lung function of patients with COPD on top of the standard medication. The effects of PBF-680 administration will also be examined with regards to symptom improvement and safety measures.One oral dose of PBF-680 or placebo will be administered daily for 4 weeks after randomization. The treatments will be administered double-blind with the Investigator and patient unaware of the treatment identity. A total of 102 COPD patients, either male or female, aged 40 to 80 years (inclusive) will be randomized.

开始日期2021-12-20

申办/合作机构

Palobiofarma SL

[+1]

EUCTR2021-001732-25-ES

/ Unknown status临床2期

A phase IIa, randomized, double blind, placebo-controlled study to assess the effect of PBF-680 in patients with moderate to severe COPD on top of standard medication.

开始日期2021-08-13

申办/合作机构-

NCT03774290

/ Completed临床2期

A Phase II, Double-blind, Randomized, Parallel-group, Placebo- Controlled Multi-center Study to Investigate the Effect of the Adenosine A1 Receptor Antagonist PBF-680 on Forced Expiratory Volume in 1 Second (FEV1) in Patients With Mild-to-moderate Persistent Atopic Asthma

The present trial is an exploratory study aiming at evaluating the safety, tolerability, and efficacy of a 15-day, once daily administration of 10 mg PBF-680 in subjects with persistent, mild-to-moderate atopic asthma.

开始日期2018-06-01

申办/合作机构

Palobiofarma SL

[+1]

100 项与 PBF-680 相关的临床结果

登录后查看更多信息

100 项与 PBF-680 相关的转化医学

登录后查看更多信息

100 项与 PBF-680 相关的专利（医药）

登录后查看更多信息

100 项与 PBF-680 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性阻塞性肺疾病	临床2期	西班牙	Palobiofarma SL	2021-12-20
过敏性哮喘	药物发现	西班牙	Palobiofarma SL	2018-06-01
迟发性哮喘	药物发现	西班牙	Palobiofarma SL	2016-04-01